ArticleScandinavian journal of urology2021
The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
Article in Scandinavian journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.The New England journal of medicine · 2022Trial
- Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.The Journal of urology · 2022Trial
- Prostate Cancer Mortality in Men not Attending a Population-based Screening Program: The 'Good', the 'Bad', and the 'Ugly' After 20-yr Follow-up in the European Randomised study of Screening for Prostate Cancer.European urology open science · 2026Article
- Self-Supervised Deep Learning Framework for Rician Distribution Based Denoising and Modeling of Multi-b Prostate Diffusion MRI.Magnetic resonance in medicine · 2026Article
- Ongoing and completed clinical trials on prostate cancer screening using MRI.European radiology · 2026Review
- Evaluation of AI for prostate cancer detection in biparametric-MRI screening population data.European radiology · 2026Article
- Does It Make Sense to Perform Prostate Magnetic Resonance Imaging in Men with Normal PSA (<4 ng/mL)?Cancers · 2026Article
- Overview of Performance Indicators of Prostate Cancer Screening Trials.European urology open science · 2025Review
- Early Activation of a Multilevel Prostate Cancer Screening Model: Pilot Phase Results and Strategic Perspectives in Lombardy Region.Healthcare (Basel, Switzerland) · 2025Article
- [Early detection of prostate cancer-individualized, risk-adapted and successful].Urologie (Heidelberg, Germany) · 2025Review
- Prostate cancer diagnostics: evolution over 30 years and the impact of education level - a prospective population-based study.Frontiers in oncology · 2025Article
- Key learning on the promise and limitations of MRI in prostate cancer screening.European radiology · 2024Review
- Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial.European urology · 2024Article
- Article
- Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey.Journal of personalized medicine · 2024Article
- Manual prostate MRI segmentation by readers with different experience: a study of the learning progress.European radiology · 2024Article
- Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform.NPJ digital medicine · 2024Article
- [Prostate cancer screening-current overview].Radiologie (Heidelberg, Germany) · 2024Review
- The Lancet Commission on prostate cancer: planning for the surge in cases.Lancet (London, England) · 2024Review
- Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.World journal of urology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveTo describe the study design of the GÖTEBORG prostate cancer screening (PC) 2 (Göteborg-2), a prospective, randomised, population-based trial of PC screening. This trial evaluates whether prostate-specific antigen (PSA) testing followed by 3 Tesla prostate magnetic resonance imaging (MRI) and targeted biopsy can reduce overdiagnosis, while maintaining the detection of clinically significant cancer, compared to PSA-screening and systematic biopsy. MATERIALS AND
methodsA random sample of men 50-60 years in the Göteborg area, Sweden, identified from the Total Population Register, were randomised to either a screening or control group (CG). Participants in the screening group (SG) were further randomised into one of three arms: (1) PSA-test; if PSA ≥ 3 ng/mL, then MRI and systematic biopsy, plus targeted biopsy to suspicious lesions as per Prostate Imaging - Reporting and Data System, version 2 (PI-RADSv2) 3-5; (2) PSA-test; if PSA ≥ 3 ng/mL, then MRI, and targeted biopsy only if PI-RADSv2 3-5; (3) identical to Arm 2, except lower PSA-cut-off ≥1.8 ng/mL. The primary outcome is the detection rate of clinically insignificant PC (defined as Gleason Score 3 + 3 [Grade Group 1]) comparing all men with PSA ≥ 3 ng/mL in Arm 1
resultsRandomisation and enrolment started in September 2015. Accrual has hitherto resulted in 38,770 men randomised to the SG. The participation rate is 50%. Invitation to the first screening round was completed in June 2020.
conclusionsThe Göteborg-2 trial will provide new knowledge about the performance of prostate MRI in a screening setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.